Covid-19 Clinical Trial
Official title:
Association of the Neutrophil/Lymphocyte Ratio and Lymphocyte /Platelet Ratio With Clinical Complications and Mortality in COVID-19 Patients
There is little information about the clinical characteristics and risk factors of Covid-19
in Latin American countries considering the ethnic differences and the high prevalence of
obesity and cardiometabolic diseases. The aim of the study was to evaluate the association
between laboratory tests and the risk of complications in SARS-CoV-2 infection and to
determine their mortality risk factors in a sample of the Mexican population.
A retrospective cross-sectional study of the routinely collected data was performed in the
Hospital Regional de Alta Especialidad de Ixtapaluca (HRAEI), State of Mexico. Adult patients
(aged ≥18 years) with positive RT-PCR for SARS-CoV-2 and oxygen support that were admitted
between March 28 and May 5, 2020, were included
Data collection Data was collected deidentified admission from adult patients, with oxygen
therapy. Data were extracted from clinical medical records and the electronic database of
daily laboratory test results. Also, incomplete clinical records were included. The number of
cases in the area during the study period determined the sample size, no formal hypotheses
being implemented. All patients who met the inclusion criteria were included.
Study variables Demographic variables (sex and age), chronic medical histories (hypertension,
diabetes and cancer), laboratory plasma, and serum-based biomarkers, as well as the
mortality, mechanical ventilation, and length of stay, were considered. Leukocytosis was
considered as a leucocyte count above 10 x 103/mcL, a cut point of INL> 10, d- dimer 500 U/L,
DHL> 500U/L, low count of lymphocytes < 0·5103/mcL as risk factors exposure to death and
mechanical ventilation.
A new variable was create combining the data of neutrophil count (ANC) and lymphocyte count
(ALC) to obtain the neutrophil-to-lymphocyte ratio (NLR) (calculated dividing the ANC by the
ALC).
Outcomes The hypothesis was formulated before the statistical analysis. Our primary outcomes
were to 1) To describe the clinical characteristics of the Mexican population with SARS-CoV-2
infection, and 2) To determine the mortality risk factors in Covid-19.
Secondary outcomes included 1) To identify the chronic diseases related to Covid-19 in
Mexican population and 2) To evaluate the differences in hematic and biochemical parameters
between survivors and no survivors.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|